National
Would ENDA have a shot as a ‘jobs bill?’
Some see room for movement, others not so sure
LGBT rights supporters see room for passage of the Employment Non-Discrimination Act in the U.S. Senate during the upcoming Congress — even as Republican control of the House makes final passage of the legislation highly unlikely.
The 2010 elections left the Senate in Democratic control — although by a reduced margin — providing an opportunity for passage in that chamber if certain conditions are met.
A Republican aide, who spoke on condition of anonymity, said passage of ENDA in the Senate is “possible” provided that President Obama strongly advocates for its passage.
“You would need the kind of push that you had behind ‘Don’t Ask, Don’t Tell,'” the aide said.
Mara Keisling, executive director of the National Center for Transgender Equality, said “in theory” the Senate could pass ENDA because Democrats retained control of the chamber, although the conversations haven’t taken place yet about moving the bill forward.
Keisling added that the Senate is in a different position than it was in the previous Congress because it’s no longer trying to pass legislation that is being sent over by the House. With Republican control of the lower chamber, the Senate would be more inclined to vote on its own legislation.
“I don’t think of any us know what the Senate is going to be like this year,” she said. “The Senate wasn’t moving a lot of stuff regularly last Congress, but now that they have a different Democratic caucus, the Senate is now in a different position than they were before.”
Fred Sainz, vice president of communications for the Human Rights Campaign, said the prospects of ENDA passing in the Senate are “unknown” at this stage, but said his organization will continue to pursue all important pieces of legislation in both chambers of the next Congress.
“We think that it is important whether or not there’s Republican or Democrat control of the House that there would be a factual record that those pieces of legislation have been approved with even more co-sponsors in them,” Sainz said.
As it was introduced in the last Congress, ENDA would bar job discrimination against gay and transgender workers in most situations in the public and private workforce. Gay Rep. Barney Frank (D-Mass.) introduced the legislation in the House and Sen. Jeff Merkley (D-Ore.) introduced the bill in the Senate.
The legislation stalled in the last Congress and saw no movement in either the House or the Senate. In the House, there was speculation that opponents would use a maneuver called the motion to recommit on the floor to target the transgender language and derail the legislation. Then-House Speaker Nancy Pelosi said she wouldn’t bring ENDA up for a vote until legislative action was complete on “Don’t Ask, Don’t Tell.”
Entering the early days of the 112th Congress, activists are uncertain about the timeline for moving forward with ENDA the next time around, such as when the bill would be introduced or when hearings might take place. Julie Edwards, a Merkley spokesperson, said the senator plans to reintroduce the legislation, although she said she doesn’t yet “have a sense of timing.”
Whether Senate Majority Leader Harry Reid (D-Nev.) would bring up the legislation for a vote remains in question. Regan Lachappelle, a Reid spokesperson, said the majority leader supports ENDA, but said “Republican cooperation” will be necessary “to do anything.”
“It’s still early right now, so we’re still working on the schedule for this Congress, but it is something that he supports,” she said.
A Democratic aide, who spoke on condition of anonymity, said the possiblity for action on ENDA in the Senate would become more clear following the week on Jan. 24 when Senate leadership makes it decisions on what the legislative priorities will be.
Even if it were passed in the Senate, most observers agree that the new Republican leadership makes passing ENDA highly difficult — if not impossible. Passage in the Senate could be a symbolic vote that would build momentum in a future Congress.
Keisling said the legislation has “zero chance” of making its way to Obama’s desk because of Republican control, citing a recent Washington Blade interview with Frank in which he said there was no chance of passing any pro-LGBT legislation this Congress.
“I never say never, but I can’t imagine the circumstances in which it’ll be signed into law this Congress,” she said.
The Republican aide said just because a clear path to passage doesn’t exist in the House, advocates shouldn’t give up on moving forward in the Senate.
“You have to approach this as kind of putting bricks in the wall,” the aide said. “With hate crimes, we were lobbing it left and right for years … but that also set us up to deal with passing it rather quickly when everything happened because we were able to say it passed the Senate five times.”
Sainz said emphasizing that ENDA is at its core a “jobs” bill could enable it to pick up support in the Republican House.
“From that sense, it should appeal to members of the House — and the Senate for that matter — because it’s really doing nothing more than putting people to work, and if they can’t work, then they’re reliant on government assistance,” Sainz said. “So it should be fairly intuitive to Republicans that this is really a ‘jobs’ measure.”
At the end of the last Congress, ENDA had 45 co-sponsors in the Senate, although former Sens. Roland Burris, Ted Kaufman, Edward Kennedy and Paul Kirk were listed as co-sponsors even though they were no longer in the Senate at the end of last year. Former co-sponsors Arlen Specter, Chris Dodd and Russ Feingold have since left the Senate.
It remains to be seen whether their successors would support ENDA, although new Democrats Richard Blumenthal (D-Conn.) and Chris Coons (D-Del.) would be likely to support the legislation. Sens. Pat Toomey (R-Pa.), Scott Brown (R-Mass.), Ron Johnson (R-Wisc.) support “Don’t Ask, Don’t Tell” repeal and may also support ENDA. The offices of those senators didn’t respond to the Blade’s request for comment.
Kate Dickens, a spokesperson for Sen. Mark Kirk (R-Ill.), said the senator’s positions would be consistent “with his position on it while serving in the House — where he has been a supporter.”
One lingering question is whether a bill that includes protections on the basis of sexual orientation only — excluding the gender identity and expression provisions — would stand a better chance in the Senate or have a shot at passing in the House. In 2007, the U.S. House under Democratic control passed a non-inclusive ENDA that never saw a vote in the Senate.
The Republican aide said discussion about removing the transgender protections is a moot point because activists wouldn’t permit the removal of the legislation.
“They’re not going to, so I don’t even think it’s worth considering,” the aide said. “It’s just not worth saying ‘yes’ or ‘no.’ If it’s going to pass, it’s going to pass with the transgender in it. That’s all there is to it.”
Keisling said she thinks both a trans-inclusive and non-trans inclusive bill would have the same zero chance of making it through the House.
“There’s this weird notion that somehow Congress is fine with gay people,” she said. “It’s just not true. You saw how they tried to lay down in the road over ‘Don’t Ask, Don’t Tell.’ If Congress was so good with gay people, why are 90 percent of the gay congress people closeted?”
National
Rural LGBTQ youth face greater hurdles than urban peers: study
Online support is key for many young, queer Americans
A newly released report based on a nationwide U.S. survey of 1,267 LGBTQ young people from the age of 15 to 24 shows that LGBTQ youth living in rural communities face greater hurdles in coping with their sexual orientation or gender identity.
But the report, released by the youth advocacy organizations Hopelab and Born this Way Foundation, also shows that rural LGBTQ youth have benefited significantly by accessing online resources and support services.
The 20-page report, which was released on June 24, is entitled, “Exploring Pride and Support of LGBTQ+ Young People In Rural Communities.”
Here are the key findings of the research as stated in the report:
• Rural LGBTQ+ young people report that their schools (28% vs. 49%), communities (13% vs 35%), and households (47% vs 61%) are less supportive than those of their suburban/urban peers.
• Rural LGBTQ+ young people are significantly more likely than their suburban/urban peers to give (76% vs 70%) and receive (57% vs 51%) support through online friends and communities.
• Rural LGBTQ+ young people are significantly more likely than their suburban/urban peers to meet the threshold for depression (57% vs 45%) and report less flourishing than their suburban/urban counterparts (43% vs 52%).
• Rural LGBTQ+ young people who receive support from those they live with are more likely to be categorized as flourishing (50% vs 35%) and less likely to meet the cutoff for depression (52% vs 63%)than their counterparts with little or no support.
• Despite having less support for LGBTQ+ people in their in-person environments, rural young people report high LGBTQ+ pride at all levels comparable to their suburban/urban peers (85% vs 86%).
“The survey was developed through a collaborative process that included young people in every step, from co-designing survey methods to youth-centered co-distillation support in interpreting results,” a statement released by Hopelab and Born This Way Foundation says.
The statement adds, “The insights directly center on the perspectives of LGBTQ+ young people, ages 15-24, examining how they give and receive support online, their experiences with mental health and well-being, and ways they show kindness and offer support in the face of challenges.”
The report includes a quote from a survey interview of a participant it describes as a white, nonbinary young adult: “Being neurodivergent and Queer in a small town in the South means you’re not very likely to have friends. Finding these people online was my first gateway to being treated like a normal person by my peers. It has greatly shaped who I am today in a positive way. I think I’d still be terribly depressed had I never met them.”
The report concludes by pointing out that despite facing challenges, rural LGBTQ+ young people “demonstrate levels of pride and identity connection that are comparable to their suburban and urban peers.” It adds, “This suggests that even when direct support is lacking, many rural LGBTQ+ young people are still able to find avenues to connect to others similar to them and develop a sense of identity.”
The full report can be accessed at hopelab.org.
U.S. Supreme Court
Nine trans activists arrested outside Supreme Court
Gender Liberation Movement organized demonstration against Skrmetti ruling
On Friday afternoon, nine transgender organizers and allies were arrested on the steps of the U.S. Supreme Court for blocking the street and protesting the recent U.S. v. Skrmetti ruling.
The ruling, decided 6-3 by the conservative majority on Wednesday, upheld Tennessee’s ban on gender-affirming care for minors. The decision will allow states to pass laws restricting gender-affirming care for minors and further minimizes bodily autonomy.
The nine arrested were part of a larger group of more than 30 protesters wearing colors of the trans Pride flag— pink, blue, and white, — standing outside of the nation’s highest court. Organizers unfurled large cloths in pink, blue, and white, shared personal testimonies about how their gender-affirming care was a matter of life and death, released pink and blue smoke, and saw nine trans participants take their hormone replacement therapy.
The protest was led by the Gender Liberation Movement, an organization that “builds direct action, media, and policy interventions centering bodily autonomy, self-determination, the pursuit of fulfillment, and collectivism in the face of gender-based sociopolitical threats.” Among the nine arrested was GLM co-founder Raquel Willis.
Before being arrested, Willis spoke to multiple media outlets, explaining that this decision was an overreach of power by the Supreme Court.
“Gender-affirming care is sacred, powerful, and transformative. With this ruling in U.S. v. Skrmetti, we see just how ignorant the Supreme Court is of the experiences of trans youth and their affirming families,” said Willis. “Everyone deserves the right to holistic healthcare, and trans youth are no different. We will continue to fight for their bodily autonomy, dignity, and self-determination just like previous generations. No court, no law, no government gave us our power, and none can take it away.”
GLM co-founder Eliel Cruz also spoke to media outlets about the Skrmetti ruling, calling it “a historical moment of fascist attacks,” and encouraged the LGBTQ community to “organize and fight back.”
“As a cisgender man, I stand in solidarity with the trans community during these escalating attacks on their safety, well-being, right to exist in this world, and ability to live a future free of violence,” Cruz said. “I’m enraged at the Supreme Court’s decision to uphold a ban on gender-affirming care for youth. My heart hurts for the families and young people who this will negatively impact and harm.”
The Washington Blade reached out to Capitol Police for comment.
A spokesperson said the nine activists were arrested for violating D.C. Code §22-1307 — “Crowding, Obstructing, or Incommoding” — on First Street, N.E., after receiving three warnings.
National
FDA approves new twice-yearly HIV prevention drug
Experts say success could inhibit development of HIV vaccine
The U.S. Food and Drug Administration (FDA) on June 18 approved a newly developed HIV/AIDS prevention drug that only needs to be taken by injection once every six months.
The new drug, lenacapavir, which is being sold under the brand name of Yeztugo by the pharmaceutical company Gilead Sciences that developed it, is being hailed by some AIDS activists as a major advancement in the years-long effort to end the HIV/AIDS epidemic in the U.S. and worldwide.
Although HIV prevention drugs, known as pre-exposure prophylaxis medication or PrEP, have been available since 2012, they initially required taking one or more daily pills. More recently, another injectable PrEP drug was developed that required being administered once every two months.
Experts familiar with the PrEP programs noted that while earlier drugs were highly effective in preventing HIV infection – most were 99 percent effective – they could not be effective if those at risk for HIV who were on the drugs did not adhere to taking their daily pills or injections every two months. Experts also point out that large numbers of people at risk for HIV, especially members of minority communities, are not on PrEP and efforts to reach out to them should be expanded.
“Today marks a monumental advance in HIV prevention,” said Carl Schmid, executive director of the D.C.-based HIV + Hepatitis Policy Institute, in a statement released on the day the FDA announced its approval of lenacapavir.
“Congratulations to the many researchers who spent 19 years to get to today’s approval, backed up by the long-term investment needed to get the drug to market,” he said.
Schmid added, “Long-acting PrEP is now not only effective for up to six months but also improves adherence and will reduce HIV infections – if people are aware of it and payers, including private insurers, cover it without cost-sharing as a preventive service.”
Schmid and others monitoring the nation’s HIV/AIDS programs have warned that proposed large scale cuts in the budget for the U.S. Centers for Disease Control and Prevention by the administration of President Donald Trump could seriously harm HIV prevention programs, including PrEP-related efforts.
“Dismantling these programs means that there will be a weakened public health infrastructure and much less HIV testing, which is needed before a person can take PrEP,” Schmid said in his statement.
“Private insurers and employers must also immediately cover Yeztugo as a required preventive service, which means that PrEP users should not face any cost-sharing or utilization management barriers,” he said.
In response to a request by the Washington Blade for comment, a spokesperson for Gilead Sciences released a statement saying the annual list price per person using Yeztugo in the U.S. is $28,218. But the statement says the company is working to ensure that its HIV prevention medication is accessible to all who need it through broad coverage from health insurance companies and some of its own support programs.
“We’ve seen high insurance coverage for existing prevention options – for example, the vast majority of consumers have a $0 co-pay for Descovy for PrEP in the U.S. – and we are working to ensure broad coverage for lenacapavir [Yeztugo],” the statement says. It was referring to the earlier HIV prevention medication developed by Gilead Sciences, Descovy.
“Eligible insured people will get help with their copay,” the statement continues. “Gilead’s Advancing Access Copay Savings Program may reduce out-of-pocket costs to as little as zero dollars,” it says. “Then for people without insurance, lenacapavir may be available free of charge for those who are eligible, through Gilead’s Advancing Access Patient Assistance Program.”
Gilead Sciences has announced that in the two final trial tests for Yeztugo, which it describes as “the most intentionally inclusive HIV prevention clinical trial programs ever designed,” 99.9 percent of participants who received Yeztugo remained negative. Time magazine reports that among those who remained HIV negative at a rate of 100 percent were men who have sex with men.
Time also reports that some HIV/AIDS researchers believe the success of the HIV prevention drugs like Gilead’s Yeztugo could complicate the so-far unsuccessful efforts to develop an effective HIV vaccine.
To be able to test a potential vaccine two groups of test subjects must be used, one that receives the test vaccine and the other that receives a placebo with no drug in it.
With highly effective HIV prevention drugs now available, it could be ethically difficult to ask a test group to take a placebo and continue to be at risk for HIV, according to some researchers.
“This might take a bit of the wind out of the sails of vaccine research, because there is something so effective in preventing HIV infection,” Time quoted Dr. David Ho, a professor of microbiology, immunology, and medicine at New York’s Columbia University as saying.
Barcelona bids to host WorldPride in 2030
A Country Worth Fighting For
Garcia elected top Democrat on the House Oversight Committee
Victim of anti-gay rock-throwing assault in D.C. speaks out
Rural LGBTQ youth face greater hurdles than urban peers: study
Iranian missile destroys Tel Aviv’s last gay bar
FDA approves new twice-yearly HIV prevention drug
The forgotten struggle: LGBTQ refugees and asylum seekers in South Sudan
LGBTQ people must stand with immigrants now
